Contacts:
Direct Common Shares at a 38% Discount to WHOOP’s Recent US$10.1B Series G
WHOOP is one of the strongest private consumer health companies globally:
- 2.5M+ members
- US$1B+ revenue / run-rate
- Majority subscription revenue
- 103% YoY bookings growth
- Operating cash-flow positive in 2025
WHOOP recently raised US$575M at a US$10.1B valuation, led by Collaborative Fund, with participation from Mayo Clinic, Abbott, QIA, Mubadala, Macquarie, IVP, Cristiano Ronaldo, LeBron James, Rory McIlroy and others.
We have access to direct common shares at a material discount to the latest institutional round.
Investment Highlights
- Clean structure: exposure through an Allocations.com SPV buying WHOOP common shares directly; no layered SPV stack, no fund-of-fund structure, no forward contract, and no hidden carry.
- Company approval condition: deal only closes if WHOOP approves the transfer. This matters in a market where blocked forwards, synthetic secondaries and messy SPV layers are becoming a real concern.
- Better entry than recent investors: buying below the price paid in the March 2026 US$575M Series G.